Daniele Santini | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)	CLINICAL MEDICINE INSIGHTS: ONCOLOGY	2021
Bone metastases from urothelial carcinoma. The dark side of the moon	JOURNAL OF BONE ONCOLOGY	2021
Metastatic Renal Cell Carcinoma Classified as Good Risk: The Easiest Choice Has Become the Hardest	CHEMOTHERAPY	2021
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies	BRITISH JOURNAL OF CANCER	2021
966P Diabetes therapy burden as proxy of impairment of immune checkpoint inhibitors efficacy	ANNALS OF ONCOLOGY	2021
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients. Results of the VICTOR-6 study	BREAST CANCER RESEARCH AND TREATMENT	2021
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence	JOURNAL OF CELLULAR PHYSIOLOGY	2020
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study	EUROPEAN JOURNAL OF CANCER	2020
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer. The multicenter “SLAVE” study	CANCERS	2020
Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study	THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY	2020
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes	CLINICAL LUNG CANCER	2020
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice	JOURNAL FOR IMMUNOTHERAPY OF CANCER	2020
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study	LUNG CANCER	2020
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study	ADVANCES IN THERAPY	2020
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab	EXPERT OPINION ON BIOLOGICAL THERAPY	2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors. the multicenter FAMI-L1 study	ONCOIMMUNOLOGY	2020
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis	TARGETED ONCOLOGY	2020
Integrin alpha-5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions	JOURNAL OF BONE AND MINERAL RESEARCH	2020
Clinical outcomes of metastatic renal carcinoma following disease progression to programmed death (PD)-1 or PD-L1 inhibitors (I-O): A Meet-URO group real-world study (Meet-Uro 7)	JOURNAL OF CLINICAL ONCOLOGY	2020
Consensus molecular subtypes and CRCassigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study	JOURNAL OF CLINICAL ONCOLOGY	2020